Co-Authors
                            
                            
                                This is a "connection" page, showing publications co-authored by   LAQUISA HILL   and   CARLOS RAMOS.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.848
         
        
        
     
 
    
        
        - 
            Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 12; 30(12):1193.e1-1193.e8.
            
            
                Score: 0.231
            
         
        
        - 
            Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
            
            
                Score: 0.224
            
         
        
        - 
            Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematol Oncol Clin North Am. 2023 12; 37(6):1107-1124.
            
            
                Score: 0.212
            
         
        
        - 
            Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
            
            
                Score: 0.050
            
         
        
        - 
            Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplant. 2022 04; 57(4):579-585.
            
            
                Score: 0.048
            
         
        
        - 
            Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leuk Lymphoma. 2021 12; 62(13):3256-3263.
            
            
                Score: 0.046
            
         
        
        - 
            The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386.
            
            
                Score: 0.037